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Hyperpigmentary problems, including postinflammatory hyperpigmentation, solar lentigos, and melasma,
occur widely in the human population and are thus of broad interest for control. On the basis of genomic and
proteomic understanding of the melanocyte and melanogenesis, there are potentially hundreds of proteins and
other effectors involved in pigmentation. This knowledge, although complex, should prove most useful in
identifying specific abnormalities that lead to the hyperpigmentary problems. Also available are new laboratory
screening methods and skin color measurement tools that are increasing the pace at which materials can be
screened and evaluated clinically for their effectiveness. Combined with a clear consumer need for effective
pigmentation control agents, advanced pigmentary system understanding and new research capabilities are
setting the stage for future technological advancements.
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INTRODUCTION
There is great diversity in the color of human skin across the
globe, from the very pale color of Celtic skin to the very dark
skin types present in regions such as sub-Saharan Africa.
Across this array of skin colors, there are also many disorders
of the pigmentary system, resulting in problems ranging
from hypopigmentation to hyperpigmentation. Regardless of
the nature of the problem, the general desire is for uniformity
of skin color. This short review will focus on some specific
hyperpigmentary problems (postinflammatory hyperpigmen-
tation (PIH), solar lentigos, and melasma), investigative
methods to measure and understand the problems, and
treatment approaches.
DISCUSSION
Hyperpigmentary disorders and their causes
Postinflammatory hyperpigmentation. Skin insults that result
in inflammation can induce PIH, particularly in people with
dark skin (Pandya and Guevara, 2000; Cayce et al., 2004;
Stratigos and Katsambas, 2004; Halder and Nordlund, 2006).
Among such insults are acne lesions, ingrown hairs,
scratches, insect bites, and surfactant damage. As an example
of the latter, exposure of human forearm skin to the surfactant
sodium lauryl sulfate under patch for a few hours will
produce erythema within a day, resulting in hyperpigmenta-
tion over the course of 1–2 weeks even in Caucasian skin,
and the anti-inflammatory phytosterol will prevent this PIH
(Table 1).
Even the most common cause of hyperpigmentation
(sunlight exposure of skin) is more likely a postinflam-
matory response to UV damage to skin (Gilchrest et al., 1998;
Abdel-Malek and Kadekaro, 2006). That response may be
the result of an obvious inflammatory acute event such
as sunburn or of repeated suberythemal exposures to UV.
Although in the latter, there may not be visible erythema,
histologically, such exposed skin has elevated inflammatory
cell content, yielding a ‘‘subclinical’’ inflammatory process.
Inflammation may result in hyperpigmentation through
several mechanisms. Among them is direct stimulation
of melanocytes by inflammatory mediators such as IL-1-a,
endothelin-1, and/or stem cell factor (Sriwiriyanont et al.,
2006; Unver et al., 2006). Reactive oxygen species, such as
superoxide and nitric oxide, generated in damaged skin (for
example, from UV exposure) or released as by-products from
inflammatory cells are also known stimulators of melano-
cytes. Additionally, damage induced to epidermal cells can
lead to release of endocrine inducers of pigmentation, such
as a-melanocyte-stimulating hormone. The resulting hyper-
pigmentation induced by all these effects provides some
measure of protection against subsequent insult, as melanin
has both UV absorption and reactive oxygen species
scavenging capacity.
The melanin produced during an inflammatory event can
enter the dermis where it is engulfed by macrophages,
producing ‘‘melanophages’’ (Halder and Nordlund, 2006).
These cells are often retained in the upper dermis for
prolonged periods, as removal of dermal melanin apparently
is a very slow process. Thus, PIH can be a very long-lived
problem for the skin.
Solar (actinic) lentigos. These hyperpigmented spots are also
known as lentigines, age spots, and liver spots. They occur on
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sun-exposed parts of the body (in particular, the hands, arms,
and face), and thus most likely occur due to chronic exposure
of skin to UV and the resultant chronic inflammation. Their
dark appearance may also result, at least in part, in dermal
melanophages that have been observed histologically to
lie beneath the lentigines. Presumably, these observations
indicate that there has been a change in the genetic
expression of both the keratinocytes and the melanocyte(s)
within the spot, as compared with the melanocytes in the
surrounding nonspot skin. There are often drastic modifica-
tions of the epidermal architecture, which may, in part, be the
result of the chronic UV exposure damage associated with
spot development. The mRNA levels of melanogenesis-
associated genes (for example, POMC (proopiomelano-
cortin), tyrosinase, TYRP1 (tyrosinase-related protein 1),
DCT (dopachrome tautomerase), Pmel-17, P, MITF (micro-
phthalmia-associated transcription factor)) are all increased
in actinic lentigos. There is also an accentuation of the
epidermal endothelin cascade (endothelin-1, endothelin-
converting enzyme 1-a, endothelin-B receptor), and a role
for stem cell factor in hyperpigmentation (solar lentigos in
particular) has been identified (Kadono et al., 2001;
Imokawa, 2006; Unver et al., 2006). Additionally, alterations
in the epidermal–melanin axis and factor XIII1 melanophages
have been observed. Many of these changes appear to be
permanent, as these spots persist even when further UV
exposure is avoided (Motakawa et al., 2005). The details of
these apparent genomic expression changes have not been
defined.
Melasma. This hyperpigmentary disorder is not well under-
stood (Lee et al., 2006). It occurs typically as symmetrical
lesions on the face, primarily in darker skin type females
at puberty or later in life. Sunlight exposure is probably a
factor in the development of melasma, as it occurs on the
face (a sun-exposed body site) and as the condition worsens
in the summer. Most melasma sufferers have a hypersensi-
tivity to UV radiation, that is, they display a lower minimum
erythemal dose, and even brief exposures to sunlight
can stimulate hyperpigmentation. There is also a hormonal
component, likely progesterone, as episodes of melasma
are often associated with pregnancy and the use of hormonal
birth control. In melasma lesions, there is excess melanin
present in both the epidermis and upper dermis (associated
with extravascular macrophages). As there is only a slight
increase in number of melanocytes, the abnormality appears
to be in function of the skin cells, in particular increased
expression of a-melanocyte-stimulating hormone in kerati-
nocytes and overexpression of stem cell factor in fibroblasts
and its receptor C-kit in melanocytes of the involved
skin (Imokawa, 2004, 2006; Kang et al., 2006). In contrast
to PIH, there is no apparent inflammatory phase involved
in its development. Additionally, there is more likely a
genetic component that predisposes individuals to melasma,
although the specific genetic basis for it is not defined.
Genomics and proteomics of pigmentation
There are approximately 1500 gene products (proteins)
expressed in melanosomes of all developmental stages, with
600 of them being expressed at any given time and 100 of
them apparently unique to the melanosome (Chi et al., 2006).
Added to this are many other proteins (membrane-associated,
cytoskeletal, transport, and so on) involved in pigmentation
in both the melanocyte and the keratinocyte, indicating the
complexity of the pigmentary process and many opportu-
nities to further understand it. Although the basic process
(for example, stimulation of melanocytes and conversion
of tyrosine to melanin) is well studied, there are many
regulatory elements that have emerged from recent research
involved in signaling, in the transport of melanosomes within
the melanocyte, and the transfer of melanosomes to the
keratinocyte (Figure 1).
Less well studied are the events that occur in the
keratinocyte once melanosomes have been transferred there.
In addition to the melanosome engulfment process itself,
presumably there are intracellular signals, regulatory ele-
ments, and transport mechanisms to distribute the melano-
somes within keratinocyte. There is the process of melanin
degradation to produce ‘‘melanin dust,’’ an apparently
enzymatic process which is more active in lighter skin versus
darker skin individuals (Chen et al., 2006). This is an area ripe
for further study.
Pigmentation control agents
As noted above, as there are many processes and proteins
involved in the pigmentary process, there is a wide array
of targets against which to screen for pigmentation control
agents (Boissy, 2003; Nakayama et al., 2005). Among
the many targets are inhibitors of melanocyte stimulation
(for example, antioxidants, anti-inflammatory agents), cell
receptor antagonists (for example, a-melanocyte-stimulating
hormone antagonists), inhibitors of melanin synthesis
enzymes (for example, tyrosinase, TRP (tyrosinase-related
protein)-1, TRP-2), inhibition of melanosome transport within
the melanocyte and transfer to the keratinocyte (for example,
PAR-2 antagonists), and activators of melanin degradation
within the keratinocyte.
A classic target is inhibition of tyrosinase, the first enzyme
in the conversion of tyrosine to melanin (Nakayama et al.,
2005; Land et al., 2006). Agents such as hydroquinone, kojic
Table 1. PIH on the forearm
Test agent Erythema grade (day 2) PIH grade (day 11)
Vehicle 2.09 0.93
5% phytosterol 1.71* 0.55*
PIH, postinflammatory hyperpigmentation; SLS, sodium lauryl sulfate.
A 20% solution of SLS was applied to the forearm skin of Caucasian
subjects (n=19) under occlusive patch (0.2 ml solution in a 19-mm-
diameter chamber patch). The patch was removed after 1–4 h, depending
on the individual subject responsiveness. After washing the site to remove
surface SLS, the skin was treated topically twice daily for 5 days with test
agent. The skin was graded (0–4 grading scales) daily for erythema and
pigmentation (PIH) for 11 days (Unpublished work, D.L. Bissett).
*Statistically significantly different (Po0.05) versus vehicle.
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acid, arbutin, ascorbic acid, ellagic acid, sulfhydryl com-
pounds, and resorcinols are effective in interfering with this
process. However, as several of these materials also have
other effects, it is difficult to directly connect a specific
mechanism to the observed effect on pigmentation. For
example, sulfhydryl compounds are also effective anti-
oxidants. Table 2 overviews a short list of the many possible
targets and a few agents effective against them.
In recent work, niacinamide and NAG (N-acetyl glucosa-
mine) have been determined to be effective in reducing
melanin production in culture (Hakozaki et al., 2002; Bissett
et al., 2006). In vitro, NAG reduces production of melanin by
inhibiting activation of tyrosinase, whereas niacinamide
inhibits melanosome transfer from melanocytes to keratino-
cytes. When formulated with other cosmetic ingredients as
a skin moisturizer product (Bissett et al., 2004, 2007;
Kimball et al., 2006), a NAG/niacinamide-containing product
diminishes the appearance of hyperpigmentation (Figure 2).
Another new effective topical agent is deoxyarbutin, a
tyrosinase inhibitor (Hamed et al., 2006).
Laboratory tools
Many of the targets noted above can be investigated in
simple mechanism-specific solution assays or melanocyte
cell culture systems in the laboratory. These models permit
screening of potentially large numbers of compounds for their
inhibitory and stimulatory effects on the specific processes
being evaluated (Land et al., 2006). For example, one
screening assay involves a simple mixture of tyrosinase and
tyrosine in which a brown product (melanin) quickly appears
and can be quantified colorimetrically. Tyrosinase inhibitors,
of course, reduce the melanin produced. A simple assay of
this type can be readily performed in a 96-well plate, allow-
ing rapid robotic high-throughput screening of thousands of
compounds. Other assays, such as those involving melano-
cytes, are more complex, but even those can be constructed
in a multiwell plate format for moderate throughput screening
of potentially hundreds of compounds. Establishing an array
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Figure 1. The cycle provides the mechanism of action of various pigmentation control targets and effective agents as described in the published literature.
Table 2. Pigmentation control targets and effective
agents
Pigmentation control
target Effective agent
Tyrosinase inhibition Hydroquinone, resorcinols, kojic acid,
arbutin, ascorbic acid (vitamin C),
deoxyarbutin
Tyrosinase copper
chelation
Ellagic acid
Inhibition of tyrosinase
glycosylation
Glucosamine, N-acetyl glucosamine,
tunicamycin
Melanosome transfer Niacinamide, protease inhibitors
Downregulation of
tyrosinase
Retinoid (trans-retinoic acid, retinol and its
esters, retinaldehyde)
Antioxidant Vitamin C compounds, vitamin E, sulfhydryl
compounds
Anti-inflammatory agent Hydrocortisone, phytosterol, glycyrrhetinic
acid
Increase epidermal
turnover
Retinoids, salicylic acid
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of such simple assays permits the screening of a substantial
library of compounds through all these assays to identify
promising candidates quickly.
Another useful laboratory model that has emerged over the
past few years is the skin equivalent culture (Costello, 2000;
Klausner et al., 2000). These three-dimensional cultures can
contain both dermal and epidermal compartments, with
fibroblasts, keratinocytes, melanocytes, and potentially other
cell types. When they are raised to the air–liquid interface, the
keratinocytes will differentiate to form a stratum corneum
structure, permitting topical dosing with simple solutions
or even complex emulsion formulations or commercial
skin care products. Another particular advantage of these
cultures is that they are not mechanism specific—as all
the pigmentation machinery is present in the cultures,
they potentially can be responsive to materials that affect
any of the pigmentation targets. These cultures are available
from commercial suppliers. Although these are useful tools
for material evaluation, they are relatively low throughput,
particularly due to the high cost of the cultures. The final
proof of value, although, requires progressing materials from
the laboratory to clinical testing to demonstrate on-skin
activity.
Additionally, a new imaging method has emerged that
specifically measures the melanin chromophore (Moncrieff
et al., 2002; Preece et al., 2003; Matts et al., 2007). This
noninvasive method is a useful addition to the existing
clinical tools to detect changes in skin melanin content and
specifically distribution, regardless of the presence of other
skin chromophores (for example, hemoglobin).
CONCLUSION
An increased understanding of the pigmentation process
provides a basis for establishing targets against which to
screen new compounds to identify those that may be effective
pigmentation control agents. With the advances in laboratory
and clinical methodology, the screening process can occur
much more rapidly than in the past. In addition, there
continues to be a clear consumer need for new and effective
pigmentation control agents, particularly as the long-used
over-the-counter technology hydroquinone, which was
already banned in Europe and Japan, is likely soon to be
banned in the United States over concerns such as cyto-
toxicity. This fuels the need for additional options effective
for problems of skin hyperpigmentation.
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Figure 2. Computer image analysis of Caucasian facial digital images
(n¼ 35) for change in spot area fraction. More negative numbers indicate
reduction in hyperpigmentation (improvement). The P-value is for 4% Nþ 2%
NAG versus 4% N. N, niacinamide; NAG, N-acetyl glucosamine.
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